These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 33045196)

  • 1. The epigenetic treatment remodel genome-wide histone H4 hyper-acetylation patterns and affect signaling pathways in acute promyelocytic leukemia cells.
    Valiulienė G; Vitkevičienė A; Navakauskienė R
    Eur J Pharmacol; 2020 Dec; 889():173641. PubMed ID: 33045196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-leukemic effects of HDACi Belinostat and HMTi 3-Deazaneplanocin A on human acute promyelocytic leukemia cells.
    Valiulienė G; Stirblytė I; Jasnauskaitė M; Borutinskaitė V; Navakauskienė R
    Eur J Pharmacol; 2017 Mar; 799():143-153. PubMed ID: 28192098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Belinostat, a potent HDACi, exerts antileukaemic effect in human acute promyelocytic leukaemia cells via chromatin remodelling.
    Valiuliene G; Stirblyte I; Cicenaite D; Kaupinis A; Valius M; Navakauskiene R
    J Cell Mol Med; 2015 Jul; 19(7):1742-55. PubMed ID: 25864732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone deacetylase inhibitor belinostat in human acute promyelocytic leukemia cells.
    Savickiene J; Treigyte G; Valiuliene G; Stirblyte I; Navakauskiene R
    Anticancer Drugs; 2014 Sep; 25(8):938-49. PubMed ID: 24800886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone modifications patterns in tissues and tumours from acute promyelocytic leukemia xenograft model in response to combined epigenetic therapy.
    Valiulienė G; Treigytė G; Savickienė J; Matuzevičius D; Alksnė M; Jarašienė-Burinskaja R; Bukelskienė V; Navakauskas D; Navakauskienė R
    Biomed Pharmacother; 2016 Apr; 79():62-70. PubMed ID: 27044813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C/EBPα and PU.1 are involved in distinct differentiation responses of acute promyelocytic leukemia HL-60 and NB4 cells via chromatin remodeling.
    Savickiene J; Treigyte G; Vistartaite G; Tunaitis V; Magnusson KE; Navakauskiene R
    Differentiation; 2011 Jan; 81(1):57-67. PubMed ID: 20864248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential gene expression in retinoic acid-induced differentiation of acute promyelocytic leukemia cells, NB4 and HL-60 cells.
    Lee KH; Chang MY; Ahn JI; Yu DH; Jung SS; Choi JH; Noh YH; Lee YS; Ahn MJ
    Biochem Biophys Res Commun; 2002 Sep; 296(5):1125-33. PubMed ID: 12207890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase inhibition promotes osteoblast maturation by altering the histone H4 epigenome and reduces Akt phosphorylation.
    Dudakovic A; Evans JM; Li Y; Middha S; McGee-Lawrence ME; van Wijnen AJ; Westendorf JJ
    J Biol Chem; 2013 Oct; 288(40):28783-91. PubMed ID: 23940046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Restoration of CCAAT enhancer binding protein α P42 induces myeloid differentiation and overcomes all-trans retinoic acid resistance in human acute promyelocytic leukemia NB4-R1 cells.
    Wang L; Xiao H; Zhang X; Liao W; Fu S; Huang H
    Int J Oncol; 2015 Nov; 47(5):1685-95. PubMed ID: 26397153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Green tea polyphenol EGCG causes anti-cancerous epigenetic modulations in acute promyelocytic leukemia cells.
    Borutinskaitė V; Virkšaitė A; Gudelytė G; Navakauskienė R
    Leuk Lymphoma; 2018 Feb; 59(2):469-478. PubMed ID: 28641467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells.
    Nishioka C; Ikezoe T; Yang J; Koeffler HP; Yokoyama A
    Leukemia; 2008 Dec; 22(12):2159-68. PubMed ID: 18784743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antileukemic activity of combined epigenetic agents, DNMT inhibitors zebularine and RG108 with HDAC inhibitors, against promyelocytic leukemia HL-60 cells.
    Savickiene J; Treigyte G; Borutinskaite VV; Navakauskiene R
    Cell Mol Biol Lett; 2012 Dec; 17(4):501-25. PubMed ID: 22820861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic changes by zebularine leading to enhanced differentiation of human promyelocytic leukemia NB4 and KG1 cells.
    Savickiene J; Treigyte G; Jonusiene V; Bruzaite R; Borutinskaite VV; Navakauskiene R
    Mol Cell Biochem; 2012 Jan; 359(1-2):245-61. PubMed ID: 21842375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone Acetyltransferase p300/CREB-binding Protein-associated Factor (PCAF) Is Required for All-
    Sunami Y; Araki M; Kan S; Ito A; Hironaka Y; Imai M; Morishita S; Ohsaka A; Komatsu N
    J Biol Chem; 2017 Feb; 292(7):2815-2829. PubMed ID: 28053092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complex context relationships between DNA methylation and accessibility, histone marks, and hTERT gene expression in acute promyelocytic leukemia cells: perspectives for all-trans retinoic acid in cancer therapy.
    Garsuault D; Bouyer C; Nguyen E; Kandhari R; Prochazkova-Carlotti M; Chevret E; Forgez P; Ségal-Bendirdjian E
    Mol Oncol; 2020 Jun; 14(6):1310-1326. PubMed ID: 32239597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo effects of a histone deacetylase inhibitor, FK228, on human acute promyelocytic leukemia in NOD / Shi-scid/scid mice.
    Kosugi H; Ito M; Yamamoto Y; Towatari M; Ito M; Ueda R; Saito H; Naoe T
    Jpn J Cancer Res; 2001 May; 92(5):529-36. PubMed ID: 11376562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia.
    He LZ; Tolentino T; Grayson P; Zhong S; Warrell RP; Rifkind RA; Marks PA; Richon VM; Pandolfi PP
    J Clin Invest; 2001 Nov; 108(9):1321-30. PubMed ID: 11696577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of a histone deacetylase inhibitor (PXD101) for thyroid cancer treatment.
    Lin SF; Lin JD; Chou TC; Huang YY; Wong RJ
    PLoS One; 2013; 8(10):e77684. PubMed ID: 24155971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PML-RARalpha/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia.
    Martens JH; Brinkman AB; Simmer F; Francoijs KJ; Nebbioso A; Ferrara F; Altucci L; Stunnenberg HG
    Cancer Cell; 2010 Feb; 17(2):173-85. PubMed ID: 20159609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Euchromatic histone methyltransferase 2 inhibitor, BIX-01294, sensitizes human promyelocytic leukemia HL-60 and NB4 cells to growth inhibition and differentiation.
    Savickiene J; Treigyte G; Stirblyte I; Valiuliene G; Navakauskiene R
    Leuk Res; 2014 Jul; 38(7):822-9. PubMed ID: 24832370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.